

1. Record Nr.	UNINA9910483266403321
Autore	T Devasena
Titolo	Nanotechnology-COVID-19 interface / / Devasena T
Pubbl/distr/stampa	Gateway East, Singapore : , : Springer, , [2021] Â©2021
ISBN	981-336-300-2
Edizione	[1st ed. 2021.]
Descrizione fisica	1 online resource (VIII, 142 p. 12 illus.)
Collana	SpringerBriefs in applied sciences and technology. Nanotheranostics
Disciplina	614.592414
Soggetti	COVID-19 (Disease)
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references.
Nota di contenuto	1. introduction to COVID-19 -- 2. STRUCTURE OF SARS COV2 -- 3. TROPISM OF SARS COV2 -- 4. NANOTECHNOLOGY-COVID 19 INTERFACE -- 5. NANOPARTICLES IN DIAGNOSIS OF COVID-19.
Sommario/riassunto	This book highlights the role of nanotechnology concepts in the management of COVID-19 pandemic. The book covers different aspects of the causative agent SARS CoV2 (Severe Acute Respiratory Syndrome Coronavirus-2) and the COVID-19 pandemic with a special emphasis on nanotechnology. It discusses the origin and history of SARS CoV2 and the outbreak of COVID-19 and highlights the geographical mutations in the SARS CoV2 virus genome, providing information about the structural features, antigenicity and the life cycle of SARS CoV2. The book provides an insight into nanotechnology–virology interface and explains how nanomaterials link the gap between the vital phases of SARS CoV2 life cycle and the four modalities of COVID-19 management viz sensing/diagnosis, therapy, prevention and self-protection. Further, the existing and promising diagnostic tools for detection of COVID-19 are discussed with an emphasis on nano PCR, nanoimmunosensors, biobarcode assay and point of care approach and also describe the nanoparticles involved in the CT imaging of lungs and SFHI (Spatial Frequency Hetrodyne Imaging) for diagnosis of SARS COV2 infection. The book concludes with details about translational medicine and explains the types of SARS CoV2 vaccines, stages of COVID-19 vaccine development and possible nanovaccines for COVID-19,

followed by the description on biopharmaceutical companies involved  
in the production of SARS CoV2 vaccines.

---